Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dose-escalation study of ORGN001 (rcPMP) in pediatric Molybdenum Cofactor Deficiency Type A
2013-002701-56Phase 2Unknown
- Sponsor
- Origin Biosciences, Inc.
- Start
- Dec 2013
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosdenopterin in molybdenum cofactor deficiency type A (MoCD-A), sponsored by Origin Biosciences, Inc. Primary endpoint: Safety endpoints. Status: unknown.
02
Drugs
fosdenopterin
03
Conditions
molybdenum cofactor deficiency type A (MoCD-A)
Beyond the preview
Go deeper on 2013-002701-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002701-56.